Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-211 vs Topotecan in relapsed ovarian cancer
NCT00046800Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2002
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 2
01
Overview
A Phase 2 trial of lurtotecan liposome in Epithelial Ovarian Cancer (EOC), sponsored by Astellas Pharma. Started Sep 2002; status: completed.
02
Drugs
lurtotecan liposome
03
Conditions
Epithelial Ovarian Cancer (EOC)
Beyond the preview
Go deeper on NCT00046800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046800.